Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia

  • Simpson E
  • Lin Y
  • Stanworth S
  • et al.
125Citations
Citations of this article
160Readers
Mendeley users who have this article in their library.
Get full text
This PDF is freely available from an open access repository. It may not have been peer-reviewed.

Abstract

BACKGROUND: Recombinant factor VIIa (rFVIIa) is licensed for use in patients with haemophilia and inhibitory allo-antibodies. It is also increasingly being used for off-license indications to prevent bleeding in operations where blood loss is likely to be high, and/or to stop bleeding that is proving difficult to control by other means.

Cite

CITATION STYLE

APA

Simpson, E., Lin, Y., Stanworth, S., Birchall, J., Doree, C., & Hyde, C. (2012). Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd005011.pub4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free